The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
E. Van Cutsem
Disclosure not yet available
C. Boni
Disclosure not yet available
J. Tabernero
Disclosure not yet available
B. Massuti
Disclosure not yet available
D. A. Richards
Disclosure not yet available
H. Prenen
Disclosure not yet available
I. Steinberg
Disclosure not yet available
P. Rougier
Disclosure not yet available